Skip to content

MBX

MBX Biosciences, Inc. Common Stock

NASDAQ · USHealthcareBiotechnology
$60.14-4.42%

Price as of Jul 20, 2026

MBX growth

MBX Biosciences, Inc. Common Stock growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
EBITDA
-10.0%
EBIT
-21.4%
EPS
+0.0%
Free cash flow
-18.6%
Operating cash flow
-16.2%

Forward estimates

Revenue
EBITDA
EPS
-79.7%

Three-year CAGR

Revenue
EBITDA
-40.6%
EBIT
-43.8%
Net income
-40.5%
EPS
-28.6%
Free cash flow
-47.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.